Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials

Table 3 The subgroup analysis for PFS in patients with PROC

Subgroup		Pooled OS		Heterogeneity
Subgroup		HR[95% CI]	p	I²	p
Combination therapeutic agents	Chemotherapy	0.49[0.42,0.57]	0.000	0%	0.525
Combination therapeutic agents	PARP inhibitors	0.76[0.50,1.15]	0.192	-	-
Trial phase	phase II	0.54[0.45,0.64]	0.000	28.7%	0.209
Trial phase	phase III	0.48[0.38,0.60]	0.000	-	-
Region	non-Asia	0.51[0.44,0.60]	0.000	49.6%	0.094
Region	Asia	0.52[0.38,0.70]	0.000	0%	0.588
ECOG	0–2	0.49[0.42,0.57]	0.000	0%	0.416
ECOG	0–4	0.67[0.48,0.92]	0.013	2.6%	0.311
Primary tumor site	OC, FTC, PC	0.51[0.44,0.59]	0.000	40%	0.139
Primary tumor site	OC	0.59[0.39,0.88]	0.01	0%	0.618
Publication year	within 5 years	0.55[0.46,0.67]	0.000	32.4%	0.193
Publication year	5 years ago	0.47[0.38,0.58]	0.000	0%	0.638

ISSN: 1472-6874